Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab versus intravenous methylprednisolone for active thyroid-associated ophthalmopathy
2007-003910-33Phase 3Active
- Sponsor
- Policlinico di Milano
- Start
- Jan 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Graves Orbitopathy (GO) comparing Rituximab with Intravenous methylprednisolone (2 arms). Primary endpoint: Clinical activity score response. Started Jan 2008; status: active.
02
Drugs
rituximabmethylprednisolone
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2007-003910-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003910-33.